InnoCare Pharma (HKSE:09969) Total Inventories : HK$130.3 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Total Inventories?

InnoCare Pharma's total inventories for the quarter that ended in Dec. 2023 was HK$130.3 Mil. InnoCare Pharma's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was HK$127.8 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. InnoCare Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$3.55.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. InnoCare Pharma's Days Inventory for the three months ended in Dec. 2023 was 387.05.

Inventory Turnover measures how fast the company turns over its inventory within a year. InnoCare Pharma's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.24.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. InnoCare Pharma's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.58.

InnoCare Pharma Total Inventories Historical Data

The historical data trend for InnoCare Pharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Total Inventories Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

2.23

12.14

72.95

130.26

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial												72.95	119.75	125.41	130.26	-

InnoCare Pharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

InnoCare Pharma (HKSE:09969) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

InnoCare Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(8995.889	+	0.75 * 302.734	+	0.5 * 130.264	-	2995.23
-	0	-	35.938)	/	1763.13
=	3.55

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

InnoCare Pharma's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	127.8375	/	30.139	*	365 / 4
	=	387.05

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

InnoCare Pharma's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	30.139	/	127.8375
	=	0.24

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

InnoCare Pharma's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	127.8375	/	220.041
	=	0.58

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

InnoCare Pharma Total Inventories Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines